Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

(2012) Robyn M. Emanuel et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

(2011) A. Alvarez-Larran et al.   BLOOD

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

(2011) R. Scherber et al.   BLOOD

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

(2011) G Barosi et al.   LEUKEMIA

Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria

(2010) A. Carobbio et al.   BLOOD

Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells

(2010) J-J Kiladjian et al.   LEUKEMIA

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD